Filing Details
- Accession Number:
- 0001209191-20-042479
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-07-15 13:22:40
- Reporting Period:
- 2020-07-13
- Accepted Time:
- 2020-07-15 13:22:40
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1515673 | Ultragenyx Pharmaceutical Inc. | RARE | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1248093 | D Emil Kakkis | C/O Ultragenyx Pharmaceutical Inc. 60 Leveroni Court Novato CA 94949 | President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2020-07-13 | 40,000 | $85.35 | 2,419,741 | No | 4 | S | Indirect | By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009 |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Indirect | By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009 |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 611,041 | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.74 to $87.79 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
Billionaire Hedge Funds
